Average Insider

Where insiders trade, we follow

$BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Healthcare
Sector
Drug Manufacturers - General
Industry
Christopher S. Boerner
CEO
34100
Employees
$58.80
Current Price
$122.80B
Market Cap
52W Low$47.58
Current$58.8053.3% above low, 46.7% below high
52W High$68.64

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00---
Sells00--
2 weeksBuys00---
Sells00--
1 monthBuys00--All Sells
Sells11$240,578.003,800
2 monthsBuys00--All Sells
Sells11$240,578.003,800
3 monthsBuys00--All Sells
Sells33$677,825.9310,549
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Nov 5, 2026
Haller Julia A
Director
Sale3,800$63.31$240,578.00View Details
Sep 9, 2026
Massacesi Cristian
EVP,Chief Med Offr,Head of Dev
Sale6,249$64.57$403,497.93View Details
Aug 25, 2026
Holzer Phil M
SVP and Controller
Sale500$67.50$33,750.00View Details
2 more transactions available โ€” create a free account to see 12 months of history

Upcoming Earnings

Scheduled earnings reports
Feb 4, 2027
EPS
Estimated$1.53
ActualN/A
Revenue
Estimated$12.66B
ActualN/A

Past Earnings

Historical earnings results
Oct 29, 2026
EPS
Estimated$1.10
Actual$1.35
Beat
Revenue
Estimated$12.72B
Actual$13.07B
Beat
4 more earnings records available โ€” create a free account to see 12 months of history
Version: v26.11.1